

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C12N 15/86, 15/45, C07K 14/135, 14/115, A61K 31/70</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/25858 (43) International Publication Date: 27 May 1999 (27.05.99)</p>
<p>(21) International Application Number: PCT/CA98/01064 (22) International Filing Date: 13 November 1998 (13.11.98) (30) Priority Data: 60/065,791 14 November 1997 (14.11.97) US (71) Applicant (for all designated States except US): CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Av- enue West, North York, Ontario M2R 3T4 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): PARRINGTON, Mark [CA/CA]; 45 Martin Street, Bradford, Ontario L3Z 1Z4 (CA). LI, Xiaomao [CN/CA]; 106 Glenmanor Way, Thorn- hill, Ontario L4J 3E5 (CA). (74) Agent: STEWART, Michael, I.; 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES (57) Abstract  A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed <i>in vivo</i>. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE OF INVENTIONALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES

5

FIELD OF INVENTION

The present invention relates to the field of paramyxoviridae vaccines and is particularly concerned with vaccines comprising DNA encoding the fusion (F) protein of respiratory syncytial virus (RSV) in an alphavirus vector.

BACKGROUND OF THE INVENTION

Human respiratory syncytial virus (RSV) has been identified as a major pathogen responsible for severe respiratory tract infections in infants, young children and the institutionalized elderly (refs. 1,2,3,4 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Global mortality and morbidity figures indicate that there is an urgent need for an efficacious RSV vaccine (refs. 5,6). In the USA alone, approximately 100,000 children are hospitalized annually with severe cases of pneumonia and bronchiolitis resulting from an RSV infection. Inpatient and ambulatory care for children with RSV infections has been estimated to cost in excess of \$340 million each year in the USA. The World Health Organization (WHO) and the National Institute of Allergy and Infectious Disease (NIAID) vaccine advisory

committees have ranked RSV second only to HIV for vaccine development. Both the annual morbidity and mortality figures as well as the staggering health care costs for managing RSV infections have provided the  
5 incentive for aggressively pursuing the development of efficacious RSV vaccines. However, such a vaccine is still not available.

Formalin-inactivated (FI-RSV) and live attenuated RSV vaccines have failed to demonstrate efficacy in  
10 clinical trials (refs. 7,8,9,10). Moreover, the formalin-inactivated RSV vaccine caused enhanced disease in some children following exposure to wild-type RSV (refs. 7,8,9,10). Elucidation of the mechanism(s) involved in the potentiation of RSV disease is important  
15 for the design of safe RSV vaccines, especially for the seronegative population. Recent experimental evidence suggests that an imbalance in cell-mediated responses may contribute to immunopotential. Enhanced histopathology observed in mice that were immunized with  
20 the FI-RSV and challenged with virus could be abrogated by depletion of CD4+ cells or both interleukin-4 (IL-4) and IL-10.

The RSV fusion (F) glycoprotein is one of the major immunogenic proteins of the virus. This envelope  
25 glycoprotein mediates both fusion of the virus to the host cell membrane and cell-to-cell spread of the virus (ref. 1). The F protein is synthesized as a precursor (F<sub>0</sub>) molecule which is proteolytically cleaved to form a disulphide-linked dimer composed of the N-terminal F<sub>2</sub>  
30 and C-terminal F<sub>1</sub> moieties (ref. 11). The amino acid sequence of the F protein is highly conserved among RSV

subgroups A and B and is a cross-protective antigen (refs. 6,12). In the baculovirus expression system, a truncated secreted version of the RSV F protein has been expressed in *Trichoplusia ni* insect cells (ref. 13). The  
5 recombinant protein was demonstrated to be protective in the cotton rats (ref. 13).

Studies on the development of live viral vaccines and glycoprotein subunit vaccines against parainfluenza virus infection are being pursued. Clinical trial  
10 results with a formalin-inactivated PIV types 1,2,3 vaccine demonstrated that this vaccine was not efficacious (refs. 14, 15, 16). Further development of chemically-inactivated vaccines was discontinued after clinical trials with a formalin-inactivated RSV vaccine  
15 demonstrated that not only was the vaccine not effective in preventing RSV infection but many of the vaccinees who later become infected with RSV suffered a more serious disease. Most of parainfluenza vaccine research has focused on candidate PIV-3 vaccines (ref. 17) with  
20 significantly less work being reported for PIV-1 and PIV-2. Recent approaches to PIV-3 vaccines have included the use of the closely related bovine parainfluenza virus type 3 and the generation of attenuated viruses by cold-adaptation of the virus  
25 (refs. 18, 19, 20, 21).

Another approach to parainfluenza virus type 3 vaccine development is a subunit approach focusing on the surface glycoproteins hemagglutinin-neuraminidase (HN) and the fusion (F) protein (refs. 22, 23, 24). The  
30 HN antigen, a typical type II glycoprotein, exhibits both haemagglutination and neuraminidase activities and

is responsible for the attachment of the virus to sialic acid containing host cell receptors. The type I F glycoprotein mediates fusion of the viral envelope with the cell membrane as well as cell to cell spread of the virus. It has recently been demonstrated that both the HN and F glycoproteins are required for membrane fusion. The F glycoprotein is synthesized as an inactive precursor (F) which is proteolytically cleaved into disulfide-linked F2 and F1 moieties. While the HN and F proteins of PIV-1, -2 and -3 are structurally similar, they are antigenically distinct. Neutralizing antibodies against the HN and F proteins of one of PIV type are not cross-protective. Thus, an effective PIV subunit vaccine must contain the HN and F glycoproteins from the three different types of parainfluenza viruses. Antibody to either glycoprotein is neutralizing in vitro. A direct correlation has been observed between the level of neutralizing antibody titres and resistance to PIV-3 infections in infants. Native subunit vaccines for parainfluenza virus type 3 have investigated the protectiveness of the two surface glycoproteins. Typically, the glycoproteins are extracted from virus using non-ionic detergents and further purified using lectin affinity or immunoaffinity chromatographic methods. However, neither of these techniques may be entirely suitable for large scale production of vaccines under all circumstances. In small animal protection models (hamsters and cotton rats), immunization with the glycoproteins was demonstrated to prevent infection with live PIV-3 (refs. 25, 26, 27, 28, 29).

The HN and F glycoproteins of PIV-3 have also been produced using recombinant DNA technology. HN and F glycoproteins have been produced in insect cells using the baculovirus expression system and by use of vaccinia virus and adenovirus recombinants (refs. 30, 31, 32, 33, 34). In the baculovirus expression system, both full-length and truncated forms of the PIV-3 glycoproteins as well as a chimeric F-HN fusion protein have been expressed. The recombinant proteins have been demonstrated to be protective in small animal models (see WO91/00104, US Application No. 07/773,949 filed November 29, 1991, assigned to the assignee hereof).

Semliki Forest virus (SFV) is a member of the Alphavirus genus in the Togaviridae family. The mature virus particle contains a single copy of a ssRNA genome with a positive polarity that is 5'-capped and 3'-polyadenylated. It functions as an mRNA and naked RNA can start an infection when introduced into cells. Upon infection/transfection, the 5' two-thirds of the genome is translated into a polyprotein that is processed into the four nonstructural proteins (nsP1 to 4) by self cleavage. Once the ns proteins have been synthesized they are responsible for replicating the plus-strand (42S) genome into full-length minus strands (ref. 14). These minus-strands then serve as templates for the synthesis of new plus-strand (42S) genomes and the 26S subgenomic mRNA (ref. 14). This subgenomic mRNA, which is colinear with the last one-third of the genome, encodes the SFV structural proteins.

In 1991 Liljestrom and Garoff (ref. 15) designed a series of expression vectors based on the SFV cDNA

replicon. These vectors had the virus structural protein genes deleted to make the way for heterologous inserts, but preserved the nonstructural coding region for production of the nsP1 to 4 replicase complex.

5 Short 5' and 3' sequence elements required for RNA replication were also preserved. A polylinker site was inserted downstream from the 26S promoter followed by translation stop sites in all three frames. An SpeI site was inserted just after the 3' end of the SFV cDNA  
10 for linearization of the plasmid for use in vitro transcription reactions.

Injection of SFV RNA encoding a heterologous protein have been shown to result in the expression of the foreign protein and the induction of antibody in a  
15 number of studies (refs. 16,17). The use of SFV RNA inoculation to express foreign proteins for the purpose of immunization would have several of the advantages associated with plasmid DNA immunization. For example, SFV RNA encoding a viral antigen may be introduced in  
20 the presence of antibody to that virus without a loss in potency due to neutralization by antibodies to the virus. Also, because the protein is expressed in vivo the protein should have the same conformation as the protein expressed by the virus itself. Therefore,  
25 concerns about conformational changes which could occur during protein purification leading to a loss in immunogenicity, protective epitopes and possibly immunopotential, could be avoided by plasmid DNA immunization.

30 In copending US Patent Application No. 08/476,397 filed June 7, 1995, assigned to the assignee hereof and



the disclosure of which is incorporated herein by reference (WO96/040945), there is described reference the use of plasmid vectors containing RSV F protein-encoding DNA for DNA immunization against RSV infection.

5 In copending United States Patent Application No. 08/896,500 filed July 18, 1997, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described the use of plasmid vectors containing RSV G protein-encoding DNA  
10 for DNA immunization against RSV infection.

In my copending United States Patent Application No. 08/923,558, filed September 4, 1997, assigned to the assignee hereof and the disclosure of which is incorporated by reference, I describe a DNA vector using  
15 an alphavirus vector, including Semliki Forest virus vector, containing a DNA sequence encoding a paramyxovirus protein, specifically RSV-F, for making an RNA transcript for immunization.

In WO95/27044, the disclosure of which is  
20 incorporated herein by reference, there is described the use of alphavirus cDNA vectors based on cDNA complementary to the alphavirus RNA sequence. Once transcribed from the cDNA under transcriptional control of a heterologous promoter, the alphavirus RNA is able  
25 to self-replicate by means of its own replicase and thereby amplify the copy number of the transcribed recombinant RNA molecules.

Infection with RSV leads to serious disease. It would be useful and desirable to provide improved  
30 vectors for in vivo administration of immunogenic preparations, including vaccines, for protection against

disease caused by RSV and other paramyxoviruses. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentialiation).

#### SUMMARY OF THE INVENTION

The present invention provides novel immunogenic materials and immunization procedures based on such novel materials for immunizing against disease caused by respiratory syncytial virus. In particular, the present invention is directed towards the provision of DNA vaccines against disease caused by infection with paramyxoviridae.

In accordance with one aspect of the present invention, there is provided a vector, comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; a second DNA sequence encoding a paramyxovirus protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication; the first and second DNA sequences being under transcriptional control of a promoter; and a third DNA sequence located adjacent the second DNA sequence to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.

The paramyxovirus protein may be selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV). The PIV protein may be from PIV-1, PIV-2, PIV-3 or PIV-4, particularly the  
5 HN and F glycoproteins of PIV-3. The RSV protein particularly may be the F or G glycoprotein of RSV.

The second DNA sequence may encode a full length RSV F protein, or may encode a RSV F protein lacking the transmembrane anchor and cytoplasmic tail. The  
10 lack of the coding region for the transmembrane anchor and cytoplasmic tail results in a secreted form of the RSV F protein. Alternatively, as described in the aforementioned U.S. Patent Application 08/896,500, the second DNA sequence may encode the full-length RSV-G  
15 protein or a truncated RSV G protein lacking a transmembrane region, resulting in a secreted form of the protein.

The alphavirus preferably is a Semliki Forest virus and the first DNA sequence is the Semliki Forest viral  
20 sequence contained in plasmid pSFVI.

The third nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, *in vivo*, whereby substantially all transcribed mRNA from the vector upon administration encodes the RSV protein.  
25 Such third nucleotide sequence is preferably located between the first nucleotide sequence and the promoter sequence. Such third nucleotide sequence may be that of rabbit  $\beta$ -globin intron II, as shown in Figure 8 of copending U.S. Patent Application No. 08/476,397 (WO  
30 96/040945).

The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The human cytomegalovirus Intron A sequence may be provided downstream of the promoter and upstream of the third  
5 nucleotide sequence.

A vector encoding the F protein and provided in accordance with one embodiment of the invention may be specifically pMP44, having the identifying characteristics shown in Figure 1D.

10 The vectors provided herein may be used to immunize a host against RSV infection or disease by *in vivo* expression of RSV F protein or RSV G protein, which may lack a transmembrane region, or other paramyxovirus protein, following administration of the vectors. In  
15 accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus or other paramyxovirus, which comprises administering to the host an effective  
20 amount of a vector provided herein.

The present invention also includes a novel method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G  
25 protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises isolating the gene; operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the  
30 complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-

essential for replication to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV F or G protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the alphavirus sequence; and introducing the vector into the host. A corresponding procedure may be used for other paramyxoviridae.

In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent; operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; operatively linking the first nucleotide sequence to a third nucleotide sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* from the vector in a host; and formulating the vector as a vaccine for *in vivo* administration. A corresponding procedure may be used for other paramyxoviridae.

The present invention further includes a vaccine for administration to a host, including a human host, produced by the method as well as immunogenic compositions comprising an immunoeffective amount of the  
5 vectors described herein.

#### BRIEF DESCRIPTION OF DRAWINGS

Figures 1A to 1B show a schematic of a procedure of assembly of vector pMP44;

Figures 2A to 2B show a schematic of a procedure of  
10 assembly of vector pMP44;

Figures 3A to 3E contain the nucleotide sequence of plasmid pMP44 (SEQ ID NO:1);

Figure 4 shows the anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after  
15 boosting;

Figure 5 shows the nucleotide sequence for a synthetic oligonucleotide coding for the hepatitis delta ribozyme (SEQ ID no; 2,3); and

Figures 6A to 6C show the nucleotide sequence for  
20 the SFV EcoRV-SpeI fragment ligated to the ribozyme of Figure 5 (SEQ ID no: 4).

GENERAL DESCRIPTION OF INVENTION

As described above, the present invention, in general, relates to protection of hosts against disease caused by infection by paramyxovirus by DNA immunization using DNA vectors. In particular, the invention is concerned with protection of hosts against disease caused by infection by respiratory syncytial virus (RSV), although not specifically limited thereto. The description which follows refers specifically to employing DNA sequences encoding RSV F or G protein and fragments thereof which generate antibodies which specifically react with RSV F or G protein.

In this application, the terms "RSV F protein" and "RSV G protein" are used to define a full-length RSV F or G protein, including proteins having variations in their amino acid sequences including those naturally occurring in various strain of RSV and those introduced by PCR amplification of the encoding gene while retaining the immunogenic properties, a secreted form of the RSV F or G protein lacking a transmembrane anchor and cytoplasmic tail, as well as fragments capable of generating antibodies which specifically react with RSV F or G protein and functional analogs. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof.

A vector is constructed to contain a first DNA sequence which is complementary to at least part of an

alphavirus RNA genome, specifically Semliki Forest virus, and having the complement of complete alphavirus RNA genome replication regions to permit replication *in vivo*. A second DNA sequence encoding the RSV F or G protein is inserted into a region of the first DNA sequence which is non-essential for replication. The first and second DNA sequences are under transcriptional control of a promoter to permit expression of the RSV protein in a host immunized with the vector.

10       The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 36. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as  
15       metallothionine promoter, and tissue specific promoters.

          The recombinant vector may include a third nucleotide sequence located adjacent the alphavirus sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* in a host.  
20       Such enhancement may be provided by increased *in vivo* expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter sequence and the alphavirus sequence.

25       This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription so that substantially all transcribed mRNA is intact alphavirus RNA encoding a gene of interest, for example, an RSV F protein. Specifically, rabbit  $\beta$ -  
30       globin Intron II sequence may provide such splice sites, as also described in ref. 37.



Additional enhancement may be obtained by, including an additional DNA sequence between the promoter and the enhancer sequence. Such additional DNA sequence may comprise the immediate early  
5 cytomegalovirus Intron A sequence.

The vectors provided herein, when administered to an animal, effect *in vivo* RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered and the conferring of  
10 protection. As may be seen from the results detailed in the Examples below, the DNA vectors produced a high anti-F IgG antibody titre and confer protection.

In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/476,397  
15 and 08/896,500, the vectors described herein provide a protective immune response using a lower dose and less time. In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/923,558, 08/896,550 and 08/476,397 using native RSV F, the  
20 vectors described herein produce protective immune response in the absence of pretreatment of the animal model with cardiotoxin, a material known to increase the uptake of DNA and enhance the immune response.

The vector provided herein may also comprise a  
25 fourth nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said fourth nucleotide sequence in a chimeric or a bicistronic structure. Alternatively,  
30 vectors containing the fourth nucleotide sequence may be

separately constructed and coadministered to a host, with the DNA vector provided herein.

In addition, there may be provided at the 3'-end of the Simliki Forest virus segment, a hepatitis delta virus ribosyme sequence to ensure proper *in vivo* cleavage at the 3'-end of the Simliki Forest virus sequence. Any other convenient sequence may be employed to achieve this effect.

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

#### 1. Vaccine Preparation and Use

Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F or RSV G genes and other paramyxovirus genes and vectors as disclosed herein. The vaccine elicits an immune response in a subject which includes the production of anti-F or anti-G antibodies. Immunogenic compositions, including vaccines, containing the DNA vector may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 93/24640, ref. 38) or the DNA vector may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with

polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8-hydroxybutyric acid), and polyanhydrides.

Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This  
5 delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

The RSV F or G genes and vectors may be mixed with pharmaceutically acceptable excipients which are  
10 compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents,  
15 or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site  
20 with a local anaesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to  
25 mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example,  
30 polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients,

such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1  $\mu$ g to about 1 mg of the RSV F or G genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations.

The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

In particular embodiments of the present invention, the vector comprising a first nucleotide sequence

encoding an F or G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

5       The DNA vectors may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 39) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH  
10       antibodies in the mice, while Furth et al. (ref. 40) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

## 2. Immunoassays

      The RSV F or G genes and vectors of the present  
15       invention are useful as immunogens for the generation of anti-F or anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the  
20       vector first is administered to a host to generate antibodies specific to the RSV F or G protein or other paramyxovirus protein. These RSV F- or G-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies,  
25       such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may  
30       be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the

immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

#### Biological Deposits

Certain vectors that contain the gene encoding RSV F protein and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed

22

at that time. Non-viable deposits will be replaced.  
The invention described and claimed herein is not to be  
limited in scope by plasmids deposited, since the  
deposited embodiment is intended only as an illustration  
5 of the invention. Any equivalent or similar plasmids  
that encode similar or equivalent antigens as described  
in this application are within the scope of this  
invention.

#### Deposit Summary

<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
pMP37	97905	Feb. 27, 1997
pMP42		

#### EXAMPLES

The above disclosure generally describes the  
15 present invention. A more complete understanding can  
be obtained by reference to the following specific  
Examples. These Examples are described solely for  
purposes of illustration and are not intended to limit  
the scope of the invention. Changes in form and  
20 substitution of equivalents are contemplated as  
circumstances may suggest or render expedient. Although  
specific terms have been employed herein, such terms  
are intended in a descriptive sense and not for  
purposes of limitations.

25 Methods of molecular genetics, protein  
biochemistry and immunology used but not explicitly  
described in this disclosure and these Examples are  
amply reported in the scientific literature and are  
well within the ability of those skilled in the art.



EXAMPLE 1

This Example describes a scheme for construction of a Semliki Forest Virus (SFV) DNA expression vector containing a truncated RSV F gene as outlined in  
5 Figures 1A to 1B.

Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The  $\beta$ -globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid  
10 pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT  
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT  
15 GCATGTTGATATTGAGGCTGACAGCCCATTCATCAAGTCTTTGCAGAAGGCA  
TTTCCGTCGTTGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA  
ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA  
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from  
pSFVI with primers SAL-SFV having the nucleotide  
20 sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:  
5) and ECO-SFV having the nucleotide sequence 5'-  
TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The  
resulting plasmid pMP38 was then restricted with EcoRV  
and BamHI and then dephosphorylated. Plasmid pSFV1  
25 link (see copending application no. \_\_\_\_\_ (b/o  
1038-766)) was then restricted with SpeI and ligated to  
the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and  
3). The ligation reaction was then restricted with  
EcoRV to release most of the SFV-RSVF plus ribozyme  
30 fragment. This fragment was then ligated to  
EcoRV/BamHI restricted pMP38 to produce pMP41.

Example 2

This Example describes an alternative scheme for constructing plasmid pMp44 as outlined in Figure 2.

Plasmid VR1012 was restricted with PstI and then  
5 made blunt-ended with T4 DNA polymerase. The  $\beta$ -globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the  
10 nucleotide sequence:

```
TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT
GCATGTTGATATTGAGGCTGACAGCCCATTCATCAAGTCTTTGCAGAAGGCA
TTTCCGTCGTTGAGGTGGAGTCATTGCAGGTACACCAAATGACCATGCAA
15 ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from
pSFVI with primers SAL-SFV having the nucleotide
sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:
5) and ECO-SFV having the nucleotide sequence 5'-
20 TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The
resulting plasmid pMP38 was then restricted with EcoRV
and BamHI and then dephosphorylated. Plasmid pSFV1
link (see copending application no. _____ (b/o
1038-766)) was then restricted with SpeI and ligated to
25 the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and
3).
```

The ligation reaction product was then restricted with EcoRV to release the SFV replicon plus the ribozyme having the nucleotide sequence as outlines in  
30 Figures 6A to 6C. This fragment was then ligated to the EcoRV/BamHI restricted pMP38 to produce pMP42. The

25

RSV F gene fragment was released from pMP37 by restriction with BamHI, and this fragment was ligated into the BamHI site of pMP42 to produce pMP44. The nucleotide sequence of pMP44 is shown in Figures 3A to 3E.

### EXAMPLE 3

This Example describes the immunization of mice with pMP44 and the immunogenicity results obtained.

BALB/C mice were immunized with plasmid pMP44 by the intramuscular (i.m.) route. The anterior tibialts muscles of six BALB/C mice were bilaterally injected with 2 x 100  $\mu$ g of plasmid pMP44. This amount is equivalent to approximately 94 $\mu$ g of a conventional vector, based on copy number. These mice were boosted in an identical manner 4 weeks later. The control group was immunized with 2 x 25  $\mu$ g of SFV-RSV F RNA as described in my aforementioned United States Application No. 08/923,558, except that the muscles were not pre-treated with cardiotoxin. The immunization protocol is set forth in the following Table I:

Table 1 Immunization protocol

Group	Prime	Route of Inoculation	Boost	Route of Inoculation
25	1 SFV-RSVF RNA <sup>1</sup>	Intramuscular	SFV-RSVF RNA <sup>1</sup>	Intramuscular
	2 pMP44 DNA <sup>2</sup>	Intramuscular	pMP44DNA <sup>2</sup>	Intramuscular

Mice were inoculated with:

1. 25 $\mu$ g of RNA was injected into each hind leg muscle in 50  $\mu$ L of PBS
2. 100  $\mu$ g of DNA was injected into each hind leg muscle in 50 $\mu$ L of PBS

Sera was obtained from the mice at 4 and 6 weeks. Anti-RSV F antibody titres (IgG) in these sera were determined by enzyme-linked immunosorbent assay (ELISA), as described in Example 3.

5 The anti-RSV F IgG antibody response in the sera of the BALB/C mice are summarized in Figure 4. The mice immunized with the DNA construct, pMP44, had higher anti-F titres than the mice immunized with the SFV-RSV F RNA.

10 Two weeks after the second immunization, mice were challenged intranasally with  $10^6$  plaque forming units (pfu) of the A1 strain of RSV (BG-4A). Animals were sacrificed 4 days later. Lungs were aseptically removed, weighed, and homogenized in 2 mL of complete  
15 culture medium. The virus titre in lung homogenates was determined in duplicate using vero cells, as previously described (ref. 41).

As seen in Table 2 below, immunization of mice with pMP44 DNA protected mice (5/6) against live RSV  
20 challenge, in contrast to the lack of protection when immunization with SFV-RSV F RNA was effected. This result contrasts with the complete protection which is obtained using SFV-RSV F RNA as described in U.S. Patent Application Nos. 08/923,558, 08/476,397 and  
25 08/896,500 where the results show protection after pretreatment with cardiotoxin.

Table 2

Group	Immunogen		Mean Virus Lung Titre	
	Prime	Boost	(log <sub>10</sub> /g±s.d)	% Protection
1	SFV-RSVF RNA	SFV-RSVF RNA	4.26	0
2	pMP44 DNA	pMP44DNA	2.12*	83

\* Limit of detection = 1.8

#### EXAMPLE 4

This Example describes the determination of anti-  
5 RSV F antibody titres.

Nunc-MaxiSorp plate wells were coated overnight at room temperature with 2.5 ng of immunoaffinity-purified RSV F protein diluted in 0.05M carbonate-bicarbonate buffer, pH 9.6. Wells were blocked for non-specific  
10 binding by adding 0.1% BSA in PBS for 30 min. at room temperature, followed by two washes in a washing buffer of 0.1% BSA in PBS + 0.1% Tween 20. Serial two or four-fold dilutions of mouse serum was added to the wells. After a one hour incubation at room  
15 temperature, plates were washed five times with washing buffer, and horseradish peroxidase (HRP) labeled conjugate was added at the appropriate optimal dilution in washing buffer. The total IgG assay used F(ab'), goat antimouse IgG (H+L specific)- HRP from Jackson  
20 Immuno Research Laboratory Inc. (Baltimore, MD, USA). Sheep anti-mouse IgG1-HRP from Serotec (Toronto, Ontario, Canada) was used in the IgG1 assay and goat anti-mouse IgG2a from Caltag Laboratories (San Francisco, CA, USA) was used in the IgG2a assay.  
25 Following one hour incubation at room temperature, the plates were washed five times with washing buffer, and hydrogen peroxide (substrate) in the presence of tetramethylbenzidine was added. The reaction was stopped by adding 2 M sulfuric acid. The colour was  
30 read in a Multiscan Titertek plate reader at an optical density (OD) of 450 nm. The titre was taken as the reciprocal of the last dilution at which the OD was

approximately double. This OD must be greater than the negative control of the assay at the starting dilution. The pre-immune serum of each animal was used as the negative control.

5

**SUMMARY OF THE DISCLOSURE**

In summary of this disclosure, the present invention provides certain novel alphavirus derived DNA vectors containing genes encoding RSV F or RSV G proteins, or other paramyxovirus proteins, methods of immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

10

REFERENCES

1. McIntosh K. and Chanock R.M. in Fields B.N. and Knipe D.M. (eds). Virology. Raven Press, New York, 1990, pp.1045-1072.  
5
2. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E., Collins P.L., Connors M., Karron R.A. and Chanock R.M., Virus Res 32, 13-36, 1994.  
10
3. Osterweil D. and Norman D., Am Geriat Soc 36, 659-662, 1990.
4. Agius G., Dindinand G., Biggar R.J., Peyre R., Vaillant V., Ranger S., Poupeu J.Y., Cisse M.F. and Casters M., J Med Virol 30, 117-127, 1990.  
15
5. Katz S.L. in New vaccine development establishing priorities Vol 1. National Academic Press, Washington, 1985, pp. 3974 09.  
20
6. Wertz G.W. and Sullender W.M., Biotechnology 20, 151-176, 1992 .
7. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M. and Meiklejohn G., Am J Epidemiol 89, 449-463, 1969.  
25
8. Chin J., Magoffin R.L., Shearer I.A., Schieble J.H. and Lennette E.H., Am J Epidemiol 89, 449-463, 1969.  
30
9. Belshe R.B., Van Voris L.P. and Mufson M.A., J Infect Dis 145, 311-319, 1982.  
35
10. Kim R.M., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M. and Parrott R.H., Pediatrics 48, 745-755, 1971.
11. Gruber C. and Levine S., J Gen Virol 64, 825-832, 1983.  
40
12. Olmstead R.A., Elango N. and Prince G.A., Proc Natl Acad Sci USA 83, 7462-7466, 1991.  
45

13. Parrington M., Cockle S., Wyde P., Du R.-P., Snell E., Yan W.-Y., Wang Q., Gisonni L., Sanhueza S., Ewasyshyn M. and Klein M., *Virus Genes* 14, 65-74, 1997
- 5
14. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) *Am. J. Epidemiol.* 89 (4), 435-448.
- 10
15. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) *Am. J. Epidemiol.* 89 (4), 449-463.
- 15
16. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) *J. Immunol.* 89, 216-226.
- 20
17. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke-Coelingh, K., Olmsted, R.A., Spriggs, M.K., Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.M. (1988) *Vir. Res.* 11, 1-15.
- 25
18. Hall, S.L., Sarris, C.M., Tierney, E.L., London, W.T., and Murphy, B.R. (1993) *J. Infect. Dis.* 167, 958-962.
- 30
19. Belshe, R.B., Karron, R.A., Newman, F.K., Anderson, E.L., Nugent, S.L., Steinhoff, M., Clements, M.L., Wilson, M.H., Hall, S.L., Tierney, E.L. and Murphy, B.R. (1992) *J. Clin. Microbiol.* 30 (8), 2064-2070.
- 35
20. Hall, S.L., Stokes, A., Tierney, E.L., London, W.T., Belshe, R.B., Newman, F.C. and Murphy, B.R. (1992) *Vir. Res.* 22, 173-184.
- 40
21. Van Wyke Coelingh, K.L., Winter, C.C., Tierney, E.L., London, W.T. and Murphy, B.R. (1988) *J. Infect. Dis.* 157 (4), 655-662.
- 45
22. Ray, R., Novak, M., Duncan, J.D., Matsuoka, Y. and Compans, R.W. (1993) *J. Infect. Dis.* 167, 752-755.
23. Ray, R., Brown, V.E. and Compans, R.W. (1985) *J. Infect. Dis.* 152 (6), 1219-1230.
24. Ray, R. and Compans, R.W. (1987) *J. Gen. Virol.* 68, 409-418.



25. Ray, R., Glaze, B.J., Moldoveanu, Z. and Compans, R.W. (1988) J. Infect. Dis. 157 (4), 648-654.
- 5 26. Ray, R., Matsuoka, Y., Burnett, T.L., Glaze, B.J. and Compans, R.W. (1990) J. Infect. Dis. 162, 746-749.
- 10 27. Ray, R., Glaze, B.J. and Compans, R.W. (1988) J. Virol. 62 (3), 783-787.
28. Ewasyshyn, M., Caplan, B., Bonneau A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M. (1992) Vaccine 10 (6), 412-420.
- 15 29. Ambrose, M.W., Wyde, P.R., Ewasyshyn, M., Bonneau, A.-M., Caplan, B., Meyer, H.L. and Klein, M. (1991) Vaccine 9, 505-511.
- 20 30. Kasel, J.A., Frank, A.L., Keitel, W.H., Taber, L.H., Glezen W.P. J. Virol. 1984; 52:828-32.
31. Lehman, D.J., Roof, L.L., Brideau, R.J., Aeed, P.A., Thomsen, D.R., Elhammer, A.P., Wathen, M.W. and Homa, F.L. (1993) J. Gen. Virol. 74, 459-469.
- 25 32. Brideau, R.J., Oien, N.L., Lehman, D.J., Homa, F.L. and Wathen, M.W. (1993) J. Gen. Virol. 74, 471-477.
- 30 33. Ebata, S.N., Prevec, L., Graham, F.L. and Dimock, K. (1992) Vir. Res. 24, 21-33.
34. Hall, S.L., Murphy, B.R. and Van Wyke Coelingh, K.L. (1991) Vaccine 9, 659-667.
- 35 35. Strauss E.G. and Strauss J.H., in Schlesinger S.S. and Schlesinger M.i. (eds). The Togaviridae and Flaviviridae. Plenum Press, New York, 1986, pp.35-90.
- 40 36. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., Nucl. Acids. Res. 1991, 19: 3979-3986.
- 45 37. Breathnack, R. and Harris, B.A., Nucl. Acids Res. 1983, 11: 7119-7136

38. Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90:  
11307-11311.
- 5 39. Tang et al., Nature 1992, 356: 152-154
40. Furth et al. Analytical Biochemistry, 1992, 205:  
365-368
- 10 41. Prince, G.A. et al, Am. J. Pathol. 93, 771 to 790,  
1978.

33  
CLAIMS

What we claim is:

1. A vector, comprising:
  - 5 a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; and
  - a second DNA sequence encoding a paramyxovirus
  - 10 protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication, the first and second DNA sequences being
  - 15 under transcriptional control of a promoter.
2. The vector of claim 1 wherein the paramyxovirus protein is selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial
- 20 virus (RSV).
3. The vector of claim 2 wherein the PIV protein is selected from the group consisting of PIV-1, PIV-2, PIV-3 and PIV-4
- 25
4. The vector of claim 3 wherein said PIV protein is selected from the group consisting of the HN and F glycoproteins of PIV-3.

5. The vector of claim 4 wherein the RSV protein is selected from the group consisting of the F or G glycoprotein of RSV.
- 5 6. The vector of claim 1 wherein the second DNA sequence encodes a full length RSV F or RSV G proteins.
7. The vector of claim 1, wherein the second nucleotide sequence encodes a truncated RSV F or RSV G  
10 protein lacking the transmembrane anchor and cytoplasmic tail.
8. The vector of claim 1 wherein the alphavirus is a Semliki Forest virus.
- 15 9. The vector of claim 1 wherein the first DNA sequence is the Semliki Forest viral sequence contained in plasmid pSFVI.
- 20 10. The vector of claim 1 wherein the promoter sequence is an immediate early cytomegalovirus (CMV) promoter.
11. The vector of claim 1 further comprising a third DNA sequence located adjacent the second DNA sequence  
25 to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.
12. The vector of claim 11 wherein the third nucleotide  
30 sequence comprises a pair of splice sites to prevent aberrant mRNA splicing, *in vivo* whereby substantially

35

all transcribed mRNA from the vector region  
administration encodes the RSV protein.

13. The vector of claim 12 wherein the third nucleotide  
5 sequence is located between the first nucleotide  
sequence and the promoter sequence.

14. The vector of claim 13 wherein said third  
nucleotide sequence is that of rabbit  $\beta$ -globin intron  
10 II.

15. The vector of claim 10 wherein said promoter  
sequence is an immediate early cytomegalovirus (CMV)  
promoter and the human cytomegalovirus Intron A  
15 sequence is provided downstream of the promoter and  
upstream of the third nucleotide sequence.

16. The vector of claim 15 further comprising a fourth  
nucleotide sequence at the 3'-end of the first  
20 nucleotide sequence to ensure proper *in vivo* cleavage  
at the 3'-end of the first nucleotide sequence.

17. The vector of claim 16 wherein said fourth  
nucleotide sequence is a hepatitis delta virus ribozyme  
25 sequence.

18. The vector of claim 1 which has the identifying  
characteristics of plasmid pMP44 shown in Figure 2D.

30 19. The vector of claim 1 which has SEQ ID No: 1.

20. A method of immunizing a host against disease caused by infection with paramyxovirus, which comprises administering to the host an effective amount of a vector as claimed in claim 1.

5

21. The method of claim 21 wherein said vector has the identifying characteristics of plasmid pMP44 shown in Figure 2D.

10 22. The method of claim 21 wherein said vector has SEQ ID no: 1.

23. A method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of  
15 generating antibodies which specifically react with RSV F or G protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises:

isolating said gene;

20 operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-essential for replication  
25 to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; and  
introducing the vector into the host.

24. The method of claim 23 wherein said gene encoding  
30 an RSV F protein encodes an RSV F protein lacking the transmembrane region.

25. The method of claim 24 wherein said promoter comprises the immediate early cytomegalovirus promoter.

5 26. The method of claim 25 including the step of:  
operatively linking said gene to an immunoprotective enhancing sequence to produce an enhanced immunoprotection to said RSV F protein in said host.

10

27. The method of claim 26 wherein said immunoprotective enhancing sequence is introduced into said vector between said control sequence and said gene.

15 28. The method of claim 27 wherein said immunoprotection enhancing sequence comprises a pair of splice sites to prevent aberrant mRNA splicing whereby substantially intact transcribed mRNA encodes an RSV F protein.

20

29. The method of claim 28 wherein said immunoprotection enhancing sequence is that of rabbit  $\beta$ -globin intron II.

25 30. The method of claim 23 wherein said vector is plasmid pMP44.

31. The vector of claim 23 wherein said vector has SEQ ID no: 1.

30

38

32. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent;

operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; and

formulating the vector as a vaccine for in vivo administration.

33. The composition of claim 32 wherein said vector has the identifying characteristics of pMP44 shown in Figure 2D.

34. The method of claim 32 wherein said vector has SEQ ID no: 1.

35. A vaccine for administration to a host, including a human host, produced by the method of claim 32.

36. An immunogenic composition comprising an immunoeffective amount of a vector of claim 1.

30



39

37. The composition of claim 36 wherein said vector has the identifying characteristic of pMP44 in Figure 2D.

38. The composition of claim 36 wherein said vector has

5 SEQ ID no: 1.

1/16

**Figure 4 Construction of pMP44**




Fig. 4a 1a

2/16





Fig 1B

3/16



+ Bam HI fragments  
from pMP37



Lipid



Fig 1c




FIG 10

5/16

**Figure 1 Construction of pMP44**





fig. 2A



**Figure 2** Nucleotide sequence of plasmid pMP44

```

tcgcgcgttt  cggatgatgac  ggtgaaaacc  tctgacacat  gcagctcccg  gagacgggtca  60
cagcttgtct  gtaagcggat  gccgggagca  gacaagcccg  tcagggcgcg  tcagcgggtg  120
ttggcgggtg  tcggggctgg  cttaactatg  cggcatcaga  gcagattgta  ctgagagtgc  180
accatatgcg  gtgtgaaata  ccgcacagat  gcgtaaggag  aaaataccgc  atcagattgg  240
ctattgcca  ttgcatacgt  tgtatccata  tcataatatg  tacatttata  ttggctcatg  300
tccaacatta  ccgccatgtt  gacattgatt  attgactagt  tattaatagt  aatcaattac  360
ggggtcatta  gttcatagcc  catatatgga  gttccgcgtt  acataactta  cggtaaattg  420
ccgcctggc  tgaccgcca  acgaccccg  ccattgacg  tcaataatga  cgtatgttcc  480
catagtaacg  ccaataggga  ctttccattg  acgtcaatgg  gtggagtatt  tacggtaaac  540
tgcccacttg  gcagtacatc  aagtgtatca  tatgccaaat  acgccccta  ttgacgtcaa  600
tgacggtaaa  tggcccgct  ggcattatgc  ccagtacatg  accttatggg  actttcctac  660
ttggcagtac  atctacgtat  tagtcacgc  tattaccatg  gtgatgcggg  tttggcagta  720
catcaatggg  cgtggatagc  ggtttgactc  acggggattt  ccaagtctcc  accccattga  780
cgtcaatggg  agtttgtttt  ggcacaaaa  tcaacgggac  tttccaaaat  gtcgtaacaa  840
ctccgcccc  ttgacgcaaa  tgggcggtag  gcgtgtacgg  tgggaggtct  atataagcag  900
agctcgttta  gtgaaccgtc  agatcgccg  gagacgccat  ccacgctgtt  ttgacctcca  960
tagaagacc  cgggaccgat  ccagcctccg  cggccgggaa  cgggtgcattg  gaacgcggat  1020
tccccgtgc  aagagtgcg  taagtaccgc  ctatagactc  tataggcaca  cccctttggc  1080
tcttatgcat  gctatactgt  ttttggcttg  gggcctatac  acccccgctt  ccttatgcta  1140
taggtgatgg  tatagcttag  cctatagggt  tgggttattg  accattattg  accactcccc  1200
tattggtag  gatactttcc  attactaatc  cataacatgg  ctctttgcca  caactatctc  1260
tattggctat  atgccaatac  tctgtccttc  agagactgac  acggactctg  tatttttaca  1320
ggatggggtc  ccatttatta  ttacaaaatt  cacatataca  acaacgccgt  ccccggtgce  1380
cgagttttt  attaaacata  gcgtgggatc  tccacgcgaa  tctcgggtac  gtgttccgga  1440
catgggtct  tctccggtag  cggcggagct  tccacatccg  agccctggte  ccatgcctcc  1500
agcggctcat  ggtcgtcgg  cagtccttg  ctccaaacag  tggaggccag  acttaggcac  1560
agcacaatgc  ccaccaccac  cagtgtgccg  cacaaggccg  tggcggtagg  gtatgtgtct  1620
gaaaatgagc  gtggagattg  ggctcgcacg  gctgacgcag  atggaagact  taaggcagcg  1680
gcagaagaag  atgcaggcag  ctgagttgtt  gtattctgat  aagagtcaga  ggtaactccc  1740
gttgcggtgc  tgtaacgggt  ggagggcagt  gtagtctgag  cagtactcgt  tgctgccgcg  1800
cgcgccacca  gacataatag  ctgacagact  aacagactgt  tcttttccat  gggctttttc  1860
cgatcctgag  aacttcaggg  tgagtttggt  gacccttgat  tggtctttct  ttttcgctat  1920
tgtaaaattc  atgttatatg  gagggggcaa  agttttcagg  gtgttggtta  gaatgggaag  1980
atgtcccttg  tatcaccatg  gaccctcatg  ataattttgt  ttctttcact  ttctactctg  2040
ttgacaacca  ttgtctcctc  ttattttctt  ttcattttct  gtaacttttt  cgttaaactt  2100
tagcttgcat  ttgtaacgaa  tttttaaat  cacttttggt  tatttgtag  attgtaagta  2160
ctttctctaa  tcactttttt  ttcaaggcaa  tcagggtata  ttatattgta  cttcagcaca  2220
gttttagaga  acaattgtta  taattaaatg  ataaggtaga  atatttctgc  atataaattc  2280
tggctggcgt  ggaaatattc  ttattggtag  aaacaactac  atcctggtca  tcatcctgcc  2340
tttctctta  tggttacaat  gatatacact  gtttgagatg  aggataaaat  actctgagtc  2400
caaaccgggc  ccctctgcta  accatgttca  tgcttcttc  ttttccctac  agtcctggg  2460
caacgtgctg  gttattgtgc  tgtctcatca  ttttggcaaa  gaattgtaat  acgactcact  2520
ataggcgcaa  ttgtcaccgt  cgtcgacatg  gcggatgtgt  gacatacacg  acgcaaaaag  2580
attttggtcc  agtcctgcc  acctccgcta  cgcgagagat  taaccacca  cgatggccgc  2640
caaagtgcac  gttgatattg  aggctgacag  ccattcatc  aagtctttgc  agaaggcatt  2700
tccgtcgttc  gaggtggagt  cattgcagg  cacaccaaat  gaccatgcaa  atgccagagc  2760
attttcgcac  ctggctacca  aattgatcga  gcaggagact  gacaaagaca  cactcatctt  2820
ggatatcggc  agtgcgcctt  ccaggagaat  gatgtctacg  cacaaatacc  actgcgtatg  2880
ccctatgcgc  agcgcagaag  acccgaaag  gctcgatagc  tacgcaaaga  aactggcagc  2940
ggcctccggg  aaggtgctgg  atagagagat  cgcaggaaaa  atcaccgacc  tgacagaccgt  3000
catggctacg  ccagacgctg  aatctcctac  cttttgcctg  catacagacg  tcacgtgtcg  3060
tacggcagcc  gaagtggccg  tataccagga  cgtgtatgct  gtacatgcac  caacatcgct  3120
gtaccatcag  gcgatgaaag  gtgtcagaac  ggcgtattgg  attgggtttg  acaccacccc  3180
gtttatgttt  gacgcgctag  caggcgcgta  tccaacctac  gccacaaact  gggccgacga  3240

```



```

gcaggtgtta caggccagga acataggact gtgtgcagca tccttgactg aggggaagact 3300
cggcaaaactg tccattctcc gcaagaagca attgaaacct tgcgacacag tcatgttctc 3360
ggtaggatct acattgtaca ctgagagcag aaagctactg aggagctggc acttaccctc 3420
cgtattccac ctgaaaggta aacaatcctt tacctgtagg tgcgatacca tcgtatcatg 3480
tgaagggtac gtagttaaga aaatcactat gtgccccggc ctgtacggta aaacggtagg 3540
gtacgccgtg acgtatcacg cggagggatt cctagtgtgc aagaccacag acactgtcaa 3600
aggagaaaaga gtctcattcc ctgtatgcac ctacgtcccc tcaaccatct gtgatcaaat 3660
gactggcata ctacgcaccg acgtcacacc ggaggacgca cagaagttgt tagtgggatt 3720
gaatcagagg atagttgtga acggaagaac acagcgaaac actaacacga tgaagaacta 3780
tctgcttccg attgtggccg tcgcatttag caagtgggcg agggaaataca aggcagacct 3840
tgatgatgaa aaacctctgg gtgtccgaga gaggtcactt acttgctgct gcttgtgggc 3900
atttaaaacg aggaagatgc acaccatgta caagaacca gacaccaga caatagtga 3960
ggtgccttca gattttaact cgttcgtcat cccgagccta tggctctacag gcctcgcaat 4020
cccagtcaga tcacgcatta agatgctttt ggccaagaag accaagcgag agttaatacc 4080
tgttctcgac gcgtcgtcag ccagggatgc tgaacaagag gagaaggaga ggttggaggc 4140
cgagctgact agagaagcct taccaccctc cgtcccatc gcgccggcgg agacgggagt 4200
cgtcgacgtc gacgttgaag aactagagta tcacgcaggt gcaggggtcg tggaaacacc 4260
tcgcagcgcg ttgaaagtca ccgcacagcc gaacgacgta ctactaggaa attacgtagt 4320
tctgtccccg cagaccgtgc tcaagagctc caagtggcc cccgtgcacc ctctagcaga 4380
gcaggtgaaa ataataacac ataacgggag ggccggcggg taccaggtcg acggatatga 4440
cggcagggtc ctactaccat gtggatcggc cattccggtc cctgagtttc aggttttgag 4500
cgagagcgcc actatggtgt acaacgaaag ggagttcgtc aacaggaaac tataccatat 4560
tgccgttcac ggaccgtcgc tgaacaccga cgaggagaac tacgagaaag tcagagctga 4620
aagaactgac gccgagtacg tgttcgacgt agataaaaaa tgctgcgtca agagagagga 4680
agcgtcgggt ttggtgttgg tgggagagct aaccaacccc ccgttccatg aattcgccca 4740
cgaagggctg aagatcaggc cgtcggcacc atataagact acagtagtag gagtctttgg 4800
ggttccggga tcaggcaagt ctgctattat taagagcctc gtgaccaaac acgatctggt 4860
caccagcggc aagaaggaga actgccagga aatagttaac gacgtgaaga agcaccgcgg 4920
gaaggggaca agtagggaaa acagtactc catcctgcta aacgggtgtc gtcgtgccgt 4980
ggacatccta tatgtggacg aggttttcgc ttgccattcc ggtactctgc tggccctaata 5040
tgctcttgtt aaacctcgga gcaaagtgtt gttatgcgga gaccccaagc aatgcggatt 5100
cttcaatatg atgcagctta aggtgaactt caaccacaac atctgcactg aagtatgtca 5160
taaaagtata tccagacgtt gcacgcgtcc agtcacggcc atcgtgtcta cgttgcacta 5220
cggaggcaag atgcgcacga ccaaccctgt caacaaaccc ataatcatag acaccacagg 5280
acagaccaag cccaagccag gagacatcgt gttaacatgc ttccgaggct gggcaaagca 5340
gctgcagttg gactaccgtg gacacgaagt catgacagca gcagcatctc agggcctcac 5400
ccgcaaaggg gtatacgccg taaggcagaa ggtgaatgaa aatcccttgt atgccctgc 5460
gtcggagcac gtgaatgtac tgctgacgcy cactgaggat aggtcgtgtg ggaaaacgct 5520
ggccggcgat ccctggatta aggtcctatc aaacattcca cagggttaact ttacggccac 5580
attggaagaa tggcaagaag aacacgacaa aataatgaag gtgattgaag gaccggctgc 5640
gcctgtggac gcgttccaga acaaagcgaa cgtgtgttgg gcgaaaagcc tgggtgcctgt 5700
cctggacact gccggaatca gattgacagc agaggagtgg agcaccataa ttacagcatt 5760
taaggaggac agagcttact ctccagtggg ggcttgaat gaaatttgca ccaagtacta 5820
tggagttgac ctggacagtg gcctgttttc tgccccgaag gtgtccctgt attacgagaa 5880
caaccactgg gataacagac ctggtggaag gatgtatgga ttcaatgccg caacagctgc 5940
caggctggaa gctagacata ccttcctgaa ggggcagtgg catacgggca agcaggcagt 6000
tatcgagaa agaaaaatcc aaccgcttcc tgtgctggac aatgtaattc ctatcaaccg 6060
caggctgccg cacgccctgg tggctgagta caagacgggt aaaggcagta gggttgagt 6120
gctggtcaat aaagtaagag ggtaccacgt cctgctggtg agtgagtaca acctggcttt 6180
gcctcgacgc agggtcactt ggttgtcacc gctgaatgtc acaggcgccg ataggtgcta 6240
cgacctaat ttaggactgc cggctgacgc cggcaggttc gacttggctc ttgtgaacat 6300
tcacacggaa ttcagaatcc accactacca gcagtgtgtc gaccacgcca tgaagctgca 6360
gatgcttggg ggagatgcgc tacgactgct aaaacccggc ggcatcttga tgagagctta 6420
cggatacgcc gataaaatca gcgaagccgt tgtttcctcc ttaagcagaa agttctcgtc 6480
tgcaagagtg ttgcgcccgg attgtgtcac cagcaataca gaagtgttct tgctgttctc 6540
caactttgac aacggaaaga gaccctctac gctacaccag atgaatacca agctgagtgc 6600
cgtgtatgcc ggagaagcca tgcacacggc cgggtgtgca ccctcctaca gagttaagag 6660

```

agcagacata gccacgtgca cagaagcggc tgtggttaac gcagctaabc cccgtggaac 6720  
tgtaggggat ggcgtatgca gggccgtggc gaagaaatgg ccgtcagcct ttaagggagc 6780  
agcaacacca gtgggcacaa ttaaaacagt catgtgcggc tcgtaccccg tcatccacgc 6840  
tgtagcgccct aatttctctg ccacgactga agcgggaagg gaccgcgaat tggccgctgt 6900  
ctaccgggca gtggccgccc aagtaaacag actgtcactg agcagcgtag ccatcccgtc 6960  
gctgtccaca ggagtgttca gcggcggaag agataggctg cagcaatccc tcaaccatct 7020  
attcacagca atggacgcca cggacgctga cgtgaccatc tactgcagag acaaaaagttg 7080  
ggagaagaaa atccaggaag ccattgacat gaggacggct gtggagttgc tcaatgatga 7140  
cgtggagctg accacagact tggtagaggt gcacccggac agcagcctgg tgggtcgtaa 7200  
gggctacagt accactgacg ggtcgctgta ctctactttt gaaggtacga aattcaacca 7260  
ggctgctatt gatatggcag agatactgac gttgtggccc agactgcaag aggcaaaccga 7320  
acagatatgc ctatacgcg cggcgaaac aatggacaac atcagatcca aatgtccggt 7380  
gaacgattcc gattcatcaa cacctcccag gacagtggcc tgcctgtgcc gctacgcaat 7440  
gacagcagaa cggatcgccc gccttaggtc acaccaagtt aaaagcatgg tggtttgctc 7500  
atcttttccc ctcccgaat accatgtaga tggggtgcag aaggttaagt gcgagaaggt 7560  
tctcctgttc gaccgacgg taccttcagt ggttagtccg cggaagtatg ccgcatctac 7620  
gacggaccac tcagatcggc cgttacgagg gtttgacttg gactggacca ccgactcgtc 7680  
ttccactgcc agcgatacca tgtcgctacc cagtttgca tctgtgtgaca tgcactcgat 7740  
ctacgagcca atggctccca tagtagtgac ggctgacgta caccctgaac ccgagggcat 7800  
cgcggaacct gcggcagatg tgcaccctga acccgagac catgtggacc tgcagaaccc 7860  
gattcctcca ccgcgcccga agagagctgc ataccttgcc tcccgcgcgg cgagcgacc 7920  
ggtgccggcg ccgagaaagc cgacgcctgc cccaaggact gcgtttagga acaagctgcc 7980  
tttgacgttc ggcgactttg acgagcacga ggtcgatgcg ttggcctccg ggattacttt 8040  
cggagacttc gacgacgtcc tgcgactagg ccgcgcgggt gcatatattt tctcctcgga 8100  
cactggcagc ggacatttac aacaaaaatc cgttaggcag cacaatctcc agtgcgcaca 8160  
actggatgcg gtccaggagg agaaaatgta cccgccaaaa ttggatactg agagggagaa 8220  
gctgttgctg ctgaaaatgc agatgcaccc atcggaggct aataagagtc gataccagtc 8280  
tcgcaaatgt gagaacatga aagccacggt ggtggacagg ctacatcgg gggccagatt 8340  
gtacacggga gcggacgtag gccgcatacc aacatacgcg gttcgggtacc cccgccccgt 8400  
gtactccct accgtgatcg aaagattctc aagccccgat gtagcaatcg cagcgtgcaa 8460  
cgaataccta tccagaaatt acccaacagt ggcgtcgtag cagataacag atgaatacga 8520  
cgcatacttg gacatggttg acgggtcgga tagttgcttg gacagagcga cattctgccc 8580  
ggcgaagctc cgggtgctacc cgaaacatca tgcgtaccac cagccgactg tacgcagtgc 8640  
cgtcccgtca ccctttcaga acacactaca gaacgtgcta gcggccgcca ccaagagaaa 8700  
ctgcaacgtc acgcaaatgc gagaactacc caccatggac tcggcagtggt tcaacgtgga 8760  
gtgcttcaag cgctatgcct gctccggaga atattgggaa gaatatgcta aacaacctat 8820  
ccgataaacc actgagaaca tcaactaccta tgtgacaaa ttgaaaggcc cgaaagctgc 8880  
tgcctgttc gctaagaccc acaacttggg tccgctgcag gaggttccca tggacagatt 8940  
cacggtcgac atgaaacgag atgtcaaagt cactccaggg acgaaacaca cagaggaaag 9000  
acccaaagtc caggtaattc aagcagcgga gccattggcg accgcttacc tgtgcggcat 9060  
ccacagggaa ttagtaagga gactaaatgc tgtgttacgc cctaacgtgc acacattgtt 9120  
tgatatgtcg gccgaagact ttgacgcgat catcgctct cacttccacc caggagaccc 9180  
ggttctagag acggacattg catcattcga caaaagccag gacgactcct tggctcttac 9240  
aggtttaatg atcctcgaag atctaggggt ggatcagtag ctgctggact tgatcgaggc 9300  
agcctttggg gaaatatcca gctgtcacct accaactggc acgcgcttca agttcggagc 9360  
tatgatgaaa tcgggcatgt ttctgacttt gtttattaac actgttttga acatcaccat 9420  
agcaagcagg gtactggagc agagactcac tgactccgc tgtgcggcct tcatcggcga 9480  
cgacaacatc gttcacggag tgatctccga caagctgatg gcggagaggt gcgcgtcgtg 9540  
ggtcaacatg gaggtgaaga tcattgacgc tgtcatgggc gaaaaacccc catatttttg 9600  
tgggggattc atagtttttg acagcgtcac acagaccgc tgcctgtttt cagaccact 9660  
taagcgctg ttcaagtgg gtaagccgct aacagctgaa gacaagcagg acgaagacag 9720  
gcgacgagca ctgagtacg aggttagcaa gtggttccgg acaggcttg gggccgaact 9780  
ggaggtggca ctaacatcta ggtatgaggt agagggctgc aaaagtatcc tcatagccat 9840  
ggccaccttg gcgagggaca ttaaggcgtt taagaaattg agaggacctg ttatacacct 9900  
ctacggcggc cctagattgg tgcgttaata cacagaattc tgattggatc atagcgact 9960  
attataggat ccgcgcgcgc gaattcggca cgagtaacaa tggagttgct aatcctcaa 10020  
gcaaatgcaa ttaccacaat cctcactgca gtcacatttt gttttgcttc tggcctaaaac 10080

10/16

atcactgaag aattttatca atcaacatgc agtgcagtta gcaaaggcta tcttagtgct 10140  
ctgagaactg gttggtatac cagtgttata actatagaat taagtaatat caaggaaaat 10200  
aagtgtaatg gaacagatgc taaggtaaaa ttgataaaac aagaattaga taaatataaa 10260  
aatgctgtaa cagaattgca gttgctcatg caaagcacac cagcagcaaa caatcgagcc 10320  
agaagagAAC taccaagggt tatgaattat acaactcaaca atgccaaaaa aaccaatgta 10380  
acattaagca agaaaaggaa aagaagattt cttgggtttt tgtaggtgt tggatctgca 10440  
atcgccagtg gcgttgctgt atctaagggt ctgcacctag aaggggaagt gaacaagatc 10500  
aaaagtgtc tactatccac aaacaagggt gtagtcagct tatcaaatgg agttagtgtc 10560  
ttaaccagca aagtgttaga cctcaaaaac tatatagata aacaattgtt acctattgtg 10620  
aacaagcaaa gctgcagcat atcaaatata gaaactgtga tagagttcca acaaaagaac 10680  
aacagactac tagagattac caggggaattt agtgtaaag caggtgtaac tacacctgta 10740  
agcacttaca tgttaactaa tagtgaatta ttgtcattaa tcaatgatat gcctataaca 10800  
aatgatcaga aaaagttaat gtccaacaat gttcaaatag ttagacagca aagttactct 10860  
atcatgtcca taataaaaga ggaagtctta gcatatgtag tacaattacc actatatggt 10920  
gttatagata caccctgttg gaaactacac acatcccctc tatgtacaac caacacaaaa 10980  
gaagggtcca acatctgttt aacaagaact gacagaggat ggtactgtga caatgcagga 11040  
tcagtatctt tcttcccaca agctgaaaca tgtaaagtcc aatcaaatcg agtattttgt 11100  
gacacaatga acagtttaac attaccaagt gaaataaatc tctgcaatgt tgacatatc 11160  
aaccctcaat atgattgtaa aattatgact tcaaaaacag atgtaagcag ctccgttatc 11220  
acatctctag gagccattgt gtcattgctat ggcaaaaacta aatgtacagc atccaataaa 11280  
aatcgtggaa tcataaagac atttttctaac ggggtgcgatt atgtatcaa taaagggatg 11340  
gacactgtgt ctgtaggtaa cacattatat tatgtaaata agcaagaagg taaaagtctc 11400  
tatgtaaaag gtgaaccaat aataaatttc tatgacccat tagtattccc ctctgatgaa 11460  
tttgatgcat caatatctca agtcaacgag aagattaacc agagcctagc atttattcgt 11520  
aaatccgatg aattattaca taatgtaaat gctggtaaat ccaccacaaa tatcatgact 11580  
tgataatgag gatccagatc ccgggtaatt aattgaatta catccctacg caaacgtttt 11640  
acggccgccc gtggcgcccg cggccggcgg cccgtccttg gccgttgag gccactccgg 11700  
tggtcccggt cgtccccgac ttccaggccc agcagatgca gcaactcatc agcgccgtaa 11760  
atgcgctgac aatgagacag aacgcaattg ctctctgtag gcctcccaa ccaaagaaga 11820  
agaagacaac caaaccaaag ccgaaaacgc agcccaagaa gatcaacgga aaaacgcagc 11880  
agcaaaagaa gaaagacaag caagccgaca agaagaagaa gaaaccgga aaaagagaaa 11940  
gaatgtgcat gaagattgaa aatgactgta tcttcgtatg cggctagcca cagtaacgta 12000  
gtgtttccag acatgtcggg caccgcaacta tcatgggtgc agaaaatctc ggggtggtctg 12060  
ggggccttcg caatcggcgc taccctggtg ctgggtgtgg tcaactgcat tgggctccgc 12120  
agataagtta gggtaggcaa tggcattgat atagcaagaa aattgaaaac agaaaaagtt 12180  
agggtaagca atggcatata accataactg tataacttgt aacaaagcgc aacaagacct 12240  
gcgcaattgg ccccggtggtc cgcctcacgg aaactcgggg caactcatat tgacacatta 12300  
attggcaata attggaagct tacataagct taattcgacg aataattgga tttttatttt 12360  
attttgcaat tggtttttaa tatttccaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 12420  
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaacta gcgggtcggc atggcatctc 12480  
cacctcctcg cggtccgacc tgggcatccg aaggaggacg cacgtccact cggtgggcta 12540  
agggagagat ccagatctgc tgtgccttct agttgccagc catctgttgt ttgcccctcc 12600  
cccgtgcctt ccttgaccct ggaagggtgcc actcccactg tcctttccta ataaaatgag 12660  
gaaattgcat cgcattgtct gagtaggtgt cattctattc tggggggtgg ggtggggcag 12720  
gacagcaagg gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggctct 12780  
atgggtaccc aggtgctgaa gaattgaccc ggttctctct gggccagaaa gaagcaggca 12840  
catccccttc tctgtgacac accctgtcca cggccctggt tcttagttcc agccccactc 12900  
ataggacact catagctcag gaggggtccg ccttcaatcc caccgctaa agtacttgga 12960  
gcggtctctc cctccctcat cagcccacca aaccaaactc agcctccaag agtgggaaga 13020  
aattaaagca agataggcta ttaagtgcag agggagagaa aatgcctcca acatgtgagg 13080  
aagtaatgag agaaatcata gaatttcttc cgcttctctg ctactgact cgctgcgctc 13140  
ggtcgttcgg ctgcggcgag cggtatcagc tcaactcaaag gcgtaatac ggttatccac 13200  
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa 13260  
ccgtaaaaag gccgcgttgc tggcggtttt ccataggctc cgccccctg acgagcatca 13320  
caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc 13380  
gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata 13440  
cctgtccgcc tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta 13500

6430

tctcagttcg	gtgtaggtcg	ttcgctccaa	gctgggctgt	gtgcacgaac	cccccgttca	13560
gcccgaaccgc	tgcgccttat	ccggtaacta	tcgtcttgag	tccaacccgg	taagacacga	13620
cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	atgtaggcgg	13680
tgctacagag	ttcttgaagt	ggtggcctaa	ctacggctac	actagaagaa	cagtatttgg	13740
tatctgcgct	ctgctgaagc	cagttacctt	cggaaaaaga	gttggtagct	cttgatccgg	13800
caaacaaacc	accgctggta	gcggtggttt	ttttgtttgc	aagcagcaga	ttacgcgcag	13860
aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	13920
cgaaaactca	cgttaaggga	ttttggtcat	gagattatca	aaaaggatct	tcacctagat	13980
ccttttaa	taaaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	aaacttggtc	14040
tgacagttac	caatgcttaa	tcagtgaaggc	acctatctca	gcgatctgtc	tatttcgttc	14100
atccatagtt	gcctgactcg	gggggggggg	gcgctgaggt	ctgcctcgtg	aagaagggtg	14160
tgctgactca	taccaggcct	gaatcgcccc	atcatccagc	cagaaagtga	gggagccacg	14220
gttgatgaga	gctttgttgt	aggtggacca	gttggtgatt	ttgactttt	gctttgccac	14280
ggaacggtct	gcgttgtcgg	gaagatgcgt	gatctgatcc	ttcaactcag	caaaagttcg	14340
atztatcaa	caaagccgcc	gtcccgtcaa	gtcagcgtaa	tgctctgcca	gtgttacaac	14400
caattaacca	attgtgatta	gaaaaactca	tcgagcatca	aatgaaactg	caatttattc	14460
atatcaggat	tatcaatacc	atatttttga	aaaagccgtt	tctgtaatga	aggagaaaac	14520
tcaccgaggc	agttccatag	gatggcaaga	tcctgggtatc	ggtctgcgat	tcggactcgt	14580
ccaacatcaa	tacaacctat	taatttcccc	tcgtcaaaaa	taaggttatc	aagtgagaaa	14640
tcaccatgag	tgacgactga	atccggtgag	aatggcaaaa	gcttatgcat	ttctttccag	14700
acttgttcaa	caggccagcc	attacgctcg	tcatacaaat	cactcgcatc	aaccaaaccg	14760
ttattcattc	gtgattgcgc	ctgagcgaga	cgaataacgc	gatcgctgtt	aaaaggacaa	14820
ttacaaacag	gaatcgaatg	caaccggcgc	aggaacactg	ccagcgcatc	aacaatattt	14880
tcacctgaat	caggatattc	ttctaatacc	tggaatgctg	ttttcccggg	gatcgagtg	14940
gtgagtaacc	atgcatcatc	aggagtacgg	ataaaatgct	tgatggtcgg	aagaggcata	15000
aattccgtca	gccagtttag	tctgaccatc	tcactctgtaa	catcattggc	aacgctacct	15060
ttgccatgtt	tcagaaacaa	ctctggcgca	tcgggcttcc	catacaatcg	atagattgtc	15120
gcacctgatt	gcccgaacatt	atcgcgagcc	catttatacc	catataaatc	agcatccatg	15180
ttggaattta	atcgcgccct	cgagcaagac	gtttcccggt	gaatatggct	cataacgttc	15240
cttgatttac	tgtttatgta	agcagacagt	tttattgttc	atgatgatat	atttttatct	15300
tgtgcaatgt	aacatcagag	attttgagac	acaacgtggc	tttccccccc	ccccattat	15360
tgaagcattt	atcagggtta	ttgtctcatg	agcggataca	tatttgaatg	tatttagaaa	15420
aataaacaaa	taggggttcc	gcgcacattt	ccccgaaaag	tgccacctga	cgtctaagaa	15480
accattatta	tcattgacatt	aacctataaa	aataggcgta	tcacgaggcc	ctttcgtc	15538

12/16

Figure 4. Anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after boosting




Figure 5 Ribozyme linker for pMP42

5' 3'  
CTAGCGGGTCGGCATGGCATCTCCACCTCCTCGCGGTCCGACCTGGGCATCCGAAGGAGGACGCACGTCCTCGGATGGCTAAGGGAGA  
GCCCAGCCGTACCGTAGAGGTTGAGGAGCGCCAGGCTGGACCCGTAGGCTTCCTCCTGCGTGACGGTGAGCCTACCGATTCCCTCTCTAG

Figure 6 ASFV Eco RV-Spe I fragment ligated to ribozyme

```

atcggcagtg cgccttccag gagaatgatg tctacgcaca aataccactg cgtatgccct 60
atgcgcagcg cagaagaccc cgaaaggctc gatagctacg caaagaaact ggcagcggcc 120
tccgggaagg tgctggatag agagatcgca ggaaaaatca ccgacctgca gaccgtcatg 180
5 gctacgccag acgctgaatc tctacctttt tgctgcata cagacgtcac gtgtcgtacg 240
gcagccgaag tggcgtata ccaggacgtg tatgctgtac atgcaccaac atcgtgtac 300
catcaggcga tgaagggtgt cagaacggcg tattggattg ggtttgacac caccctgttt 360
atgtttgacg cgctagcagg cgcgatatcca acctacgcca caaactgggc cgacgagcag 420
gtgttacagg ccaggaacat aggactgtgt gcagcatcct tgactgaggg aagactcggc 480
10 aaactgtcca ttctccgcaa gaagcaattg aaaccttgcg acacagtcac gttctcggta 540
ggatctacat tgtacactga gagcagaag ctactgagga gctggcactt accctccgta 600
tccacctga aaggtaaaca atcctttacc tgtagggtgcg ataccatcgt atcatgtgaa 660
gggtacgtag ttaagaaaat cactatgtgc cccggcctgt acggtaaaac ggtagggtac 720
gccgtgacgt atcacgcgga gggattccta gtgtgcaaga ccacagacac tgtcaaagga 780
15 gaaagagtct cattccctgt atgcacctac gtccctcaa ccatctgtga tcaaatgact 840
ggcatactag cgaccgacgt cacaccggag gacgcacaga agttgttagt gggattgaat 900
cagaggatag ttgtgaacgg aagaacacag cgaaacacta acacgatgaa gaactatctg 960
cttccgattg tggccgtcgc atttagcaag tgggcgaggg aatacaaggc agaccttgat 1020
gatgaaaaac ctctgggtgt ccgagagagg tcacttactt gctgtgctt gtgggcattt 1080
20 aaaacgagga agatgcacac catgtacaag aaaccagaca cccagacaat agtgaagggtg 1140
ccttcagagt ttaactcgtt cgtcatcccg agcctatggt ctacaggcct cgcaatccca 1200
gtcagatcac gcattaagat gcttttggcc aagaagacca agcgagagtt aatacctgtt 1260
ctcgacgcgt cgtcagccag ggtgtgtgaa caagaggaga aggagaggtt ggaggccgag 1320
ctgactagag aagccttacc acccctcgtc cccatcgcg cggcggagac gggagtctgc 1380
25 gacgtcgacg ttgaagaact agagtatcac gcaggtgcag gggtcgtgga aacacctcgc 1440
agcgcgttga aagtcaccgc acagccgaac gacgtactac taggaaatta cgtagtctctg 1500
tccccgcaga ccgtgctcaa gagtcccaag ttggcccccg tgcacctct agcagagcag 1560
gtgaaaataa taacacataa cgggagggcc ggcggttacc aggtcgacgg atatgacggc 1620
agggtcctac taccatgtgg atcggccatt ccggtccctg agtttcaagc tttgagcgag 1680
30 agcgccacta tgggtgtacaa cgaaagggag ttctcaaca ggaaactata ccatattgcc 1740
gttcacggac cgtcgtgtaa caccgacgag gagaactacg agaaagtcag agctgaaaga 1800
actgacgccg agtacgtgtt cgacgtagat aaaaaatgct gcgtcaagag agaggaagcg 1860
tcgggtttgg tgttgggtggg agagctaacc aacccccgt tccatgaatt cgcctacgaa 1920
gggtgaaaga tcaggccgtc ggcaccatat aagactacag tagtaggagt ctttggggtt 1980
35 ccgggatcag gcaagtctgc tattattaag agcctcgtga ccaaacacga tctggtcacc 2040
agcggcaaga aggagaactg ccaggaataa gttaacgacg tgaagaagca ccgcgggaag 2100
gggacaagta gggaaaacag tgactccatc ctgctaaacg ggtgtcgtcg tgccgtggac 2160
atcctatatg tggacgaggg tttcgtctgc cattccggta ctctgctggc cctaattgct 2220
cttgttaaac ctcgagcaa agtgggtgtt tgcggagacc ccaagcaatg cggattcttc 2280
40 aatatgatgc agcttaagggt gaacttcaac cacaacatct gcactgaagt atgtcataaa 2340
agtatatcca gacgttgac gcgtccagtc acggccatcg tgtctacgtt gcactacgga 2400
ggcaagatgc gcacgaccaa cccgtgcaac aaaccataa tcatagacac cacaggacag 2460
accaagccca agccaggaga catcgtgtta acatgcttcc gaggctgggc aaagcagctg 2520
cagttggact accgtggaca cgaagtcag acagcagcag catctcaggg cctcaccgcg 2580
45 aaaggggtat acgccgtaag gcagaagggtg aatgaaaatc ccttgtatgc ccctgcgtcg 2640
gagcacgtga atgtactgct gacgcgcact gaggataggc tgggtgtgaa aacgctggcc 2700
ggcgatccct ggattaaagg cctatcaaac attccacagg gtaactttac ggccacattg 2760
gaagaatggc aagaagaaca cgacaaaata atgaagggtg ttgaaggacc ggctgcgcct 2820
gtggacgcgt tccagaacaa agcgaacgtg tgttgggcga aaagcctggt gcctgtcctg 2880
50 gacactgccg gaatcagatt gacagcagag gagtggagca ccataattac agcatttaag 2940
gaggacagag ctactctcc agtgggtggc ttgaatgaaa tttgcaccaa gtactatgga 3000
gttgacctgg acagtggcct gttttctgcc ccgaagggtg ccctgtatta cgagaacaa 3060
cactgggata acagacctgg tggaaaggatg tatggattca atgccgcaac agctgccagg 3120
ctggaagcta gacatacctt cctgaagggg cagtggcata cgggcaagca ggcagttatc 3180
55 gcagaaagaa aaatccaacc gctttctgtg ctggacaatg taattcctat caaccgcagg 3240
ctgccgcacg ccctgggtggc tgagtacaag acggttaaag gcagtagggt tgagtggctg 3300
gtcaataaag taagagggtg ccacgtcctg ctggtgagtg agtacaacct ggctttgcct 3360
cgacgcaggg tcacttggtt gtcaccgctg aatgtcacag gcgccgatag gtgctacgac 3420

```

Ac.66

5 ctaagtttag gactgccggc tgacgccggc aggttcgact tgggtctttgt gaacattcac 3480  
acggaattca gaatccacca ctaccagcag tgtgtcgacc acgccatgaa gctgcagatg 3540  
cttgggggag atgcgctacg actgctaaaa cccggcggca tcttgatgag agcttacgga 3600  
tacgccgata aaatcagcga agccgttggt tcctccttaa gcagaaagt ctcgtctgca 3660  
agagtgttgc gcccggttg tgtcaccagc aatacagaag tgttcttgcg gttctccaac 3720  
tttgacaacg gaaagagacc ctctacgcta caccagatga ataccaagct gagtgcctg 3780  
tatgccggag aagccatgca cacggccggg tgtgcacocat cctacagagt taagagagca 3840  
gacatagcca cgtgcacaga agcggctgtg gttaacgcag ctaacgcccg tggaaactgta 3900  
ggggatggcg tatgcaggcg cgtggcgaag aaatggccgt cagcctttaa gggagcagca 3960  
10 acaccagtgg gcacaattaa aacagtcctg tgcggctcgt acccgcctat ccacgctgta 4020  
gcgcctaatt tctctgccac gactgaagcg gaaggggacc gcgaattggc cgtgtcttac 4080  
cgggcagtgg ccgccgaagt aaacagactg tcactgagca gcgtagccat cccgctgctg 4140  
tccacaggag tgttcagcgg cggagagat aggttcgacg aatccctcaa ccatctattc 4200  
acagcaatgg acgccacgga cgctgacgtg accatctact gcagagacaa aagttgggag 4260  
15 aagaaaatcc aggaagccat tgacatgagg acggtctgtg agttgctcaa tgatgacgtg 4320  
gagctgacca cagacttggt gagagtgcac ccggacagca gcctggtggg tcgtaagggc 4380  
tacagtacca ctgacgggtc gctgtactcg tactttgaag gtacgaaatt caaccaggct 4440  
gctattgata tggcagagat actgacgttg tggcccagac tgcaagaggc aaacgaaacag 4500  
atatgcctat acgcgctggg cgaacaatg gacaaatca gatccaatg tccggtgaac 4560  
20 gattccyact catcaacacc tcccaggaca gtgccctgcc tgtgcgcta cgcaatgaca 4620  
gcagaacgga tcgcccgcct taggtcacac caagttaaaa gcatggtggg ttgctcatct 4680  
tttccctccc cgaaatacca tgtagatggg gtgcagaagg taaagtgcga gaaggttctc 4740  
ctgttcgacc cgacgggtacc ttcagtgggt agtccgcgga agtatgccgc atctacgacg 4800  
gaccactcag atcggctcgt acgagggttt gacttggact ggaccacoga ctcgtcttcc 4860  
25 actgccagcg ataccatgtc gctaccaggt ttgcagtcgt gtgacatcga ctcgatctac 4920  
gagccaatgg ctcccatagt agtgacggct gacgtacacc ctgaaccgcg aggcacgcg 4980  
gacctggcgg cagatgtgca ccctgaaccc gcagaccatg tggacctcga gaacccgatt 5040  
cctccaccgc gccgaagag agctgcatac cttgcctccc gcgcggcggg gcgaccggtg 5100  
ccggcgccga gaaagccgac gcctgcccc aaggactgct ttaggaacaa gctgcctttg 5160  
30 acgttcggcg actttgacga gcacgaggtc gatgcgttg cctccgggat tactttcgga 5220  
gacttcgacg acgtcctgcg actaggccgc gcgggtgcat atattttctc ctcggacact 5280  
ggcagcggac atttacaaca aaatccgtt aggcagcaca atctccagt cgcacaactg 5340  
gatgcggtcc aggaggagaa aatgtaccgc ccaaaattgg atactgagag ggagaagctg 5400  
ttgctgctga aaatgcagat gcacccatcg gaggttaata agagtgcata ccagtctcgc 5460  
35 aaagtggaga acatgaaagc cacggtgggt gacaggctca catcgggggc cagattgtac 5520  
acgggagcgg acgtaggccg cataccaaca tacgcggttc ggtacccccg ccccggtgtac 5580  
tcccctaccg tgatcgaaag attctcaagc cccgatgtag caatcgcagc gtgcaacgaa 5640  
tacctatcca gaaattaccc aacagtggcg tcgtaccaga taacagatga ataccgacga 5700  
tacttgga ca tgggtgacgg gtcggatagt tgcttgga gaagcgacatt ctgcccggcg 5760  
40 aagctccggg gctaccgaa acatcatgcg taccaccagc cgactgtacg cagtgcctgc 5820  
cgtcaccct ttcagaacac actacagaac gtgctagcgg ccgccacca gagaaactgc 5880  
aacgtcacgc aaatgcgaga actaccacc atggactcgg cagtgttcaa cgtggagtgc 5940  
ttcaagcgct atgcctgctc cggagaatat tgggaagaat atgctaaca acctatccgg 6000  
45 ataaccactg agaacatcac tacctatgtg accaaattga aaggcccgaa agctgctgcc 6060  
ttgttcgcta agaccacaa cttggttccg ctgcaggagg ttcccatgga cagattcacg 6120  
gtcgacatga aacgagatgt caaagtcact ccagggacga aacacacaga ggaaagaccc 6180  
aaagtccagg taattcaagc agcggagcca ttggcgaccg cttacctgtg cggcatccac 6240  
agggaaattag taaggagact aaatgctgtg ttacgcccta acgtgcacac attgtttgat 6300  
atgtcggccg aagactttga cgcgatcatc gcctctcact tccaccagg agaccgggtt 6360  
50 ctagagacgg acattgcac attcgacaaa agccaggacg actccttggc tcttacaggt 6420  
ttaatgatcc tcgaagatct aggggtggat cagtacctgc tggacttgat cgaggcagcc 6480  
tttgggaaa tatccagctg tcacctacca actggcacgc gcttcaagtt cggagctatg 6540  
atgaaatcgg gcatgtttct gactttgttt attaacactg ttttgaacat caccatagca 6600  
agcagggtag tggagcagag actcactgac tccgcctgtg cggccttcat cggcgacgac 6660  
55 aacatcgctc acggagtgt ctccgacaag ctgatggcgg agaggtgcgc gtcgtgggtc 6720  
aacatggagg tgaagatcat tgacgctgtc atgggcgaaa aacccccata tttttgtggg 6780  
ggattcatag tttttgacag cgtcacacag accgcctgcc gtgtttcaga cccacttaag 6840  
cgctgttca agttgggtaa gccgctaaca gctgaagaca agcaggacga agacaggcga 6900  
cgagcactga gtgacgaggt tagcaagtgg ttccggacag gcttgggggc cgaactggag 6960



61160

gtggcactaa catctaggta tgaggtagag ggctgcaaaa gtatcctcat agccatggcc 7020  
acettggcga gggacattaa ggcgtttaag aaattgagag gacctgttat acacctctac 7080  
ggcggtccta gattggtgcg ttaatacaca gaattctgat tggatcatag cgcactatta 7140  
taggatccag atcccgggta attaattgaa ttacatecct acgcaaacgt tttacggccg 7200  
5 ccggtggcgc ccgcgcccgg cggcccgtcc ttggccggtg caggccactc cgggtggctcc 7260  
cgtcgtcccc gacttccagg ccagcagat gcagcaactc atcagcgccg taaatgcgt 7320  
gacaatgaga cagaacgcaa ttgctcctgc taggcctccc aaaccaaga agaagaagac 7380  
aaccaacca aagccgaaaa cgcagcccaa gaagatcaac ggaaaaacgc agcagcaaaa 7440  
gaagaagac aagcaagccg acaagaagaa gaagaaaccc ggaaaaagag aaagaatgtg 7500  
10 catgaagatt gaaatgact gtatcttcgt atgcggctag ccacagtaac gtagtgtttc 7560  
cagacatgtc gggcacgcga ctatcatggg tgcagaaaat ctggggtggt ctgggggcct 7620  
tcgcaatcgg cgctatcctg gtgctgggtg tggctacttg cattgggctc cgcagataag 7680  
ttagggtagg caatggcatt gatatagcaa gaaaattgaa aacagaaaaa gttagggtaa 7740  
gcaatggcat ataaccataa ctgtataact tgtaacaaag cgcaacaaga cctgcgcaat 7800  
15 tggccccgtg gtccgcctca cggaaactcg gggcaactca tattgacaca ttaattggca 7860  
ataattggaa gcttacataa gcttaattcg acgaataatt ggatttttat tttattttgc 7920  
aattggtttt taatatattcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 7980  
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ctagcgggtc ggcattggcat ctccacctcc 8040  
tcgcgggtccg acctgggcat ccgaaggagg acgcacgtcc actcggatgg ctaagggaga 8100  
20

## INTERNATIONAL SEARCH REPORT

Inter. .onal Application No

PCT/CA 98/01064

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N15/45 C07K14/135 C07K14/115 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 40945 A (CONNAUGHT LAB ;LI XIAOMAO (CA); EWASYSHYN MARY E (CA); SAMBHARA SU) 19 December 1996 cited in the application see the whole document, especially page 6, lines 2-9; page 14, lines 15-21; and page 23, lines 18-23 ---	1-36
Y	WO 95 27044 A (BIOPTION AB ;LILJESTROEM PETER (SE); GAROFF HENRIK (SE)) 12 October 1995 cited in the application see the whole document, especially page 8, lines 12-22 ---	1-36
A	WO 96 17072 A (VIAGENE INC) 6 June 1996 see the whole document --- -/--	1-36

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

23 April 1999

Date of mailing of the international search report

03/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

# INTERNATIONAL SEARCH REPORT

Inter. Patent Application No  
PCT/CA 98/01064

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHOU X. ET AL.: "Self-replicating Semliki-Forest virus RNA as recombinant vaccine" VACCINE, vol. 12, no. 16, 1994, pages 1510-1514, XP002089524 cited in the application see the whole document ----	1-36
A	LILJESTROEM P. ET AL.: "A NEW GENERATION OF ANIMAL CELL EXPRESSION VECTORS BASED ON THE SEMLIKI FOREST VIRUS REPLICON" BIO/TECHNOLOGY, vol. 9, December 1991, pages 1356-1361, XP000616021 cited in the application see the whole document ----	1-36
E,L	WO 99 11808 A (CONNAUGHT LAB ;PARRINGTON MARK (CA)) 11 March 1999  cited in the application see the whole document -----	1-9,20, 23,24, 32,35,36

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/01064

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 20-30  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01064

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640945 A	19-12-1996	AU 695527 B	13-08-1998
		AU 6117696 A	30-12-1996
		CA 2223610 A	19-12-1996
		EP 0832253 A	01-04-1998
		US 5843913 A	01-12-1998
		US 5880104 A	09-03-1999
WO 9527044 A	12-10-1995	AU 699384 B	03-12-1998
		AU 2155795 A	23-10-1995
		CA 2184261 A	12-10-1995
		EP 0753053 A	15-01-1997
		FI 963860 A	27-09-1996
		JP 9511143 T	11-11-1997
WO 9617072 A	06-06-1996	AU 4594996 A	19-06-1996
		EP 0797679 A	01-10-1997
		US 5814482 A	29-09-1998
		US 5843723 A	01-12-1998
		US 5789245 A	04-08-1998
WO 9911808 A	11-03-1999	NONE	